Eribulin mesylate in Advanced Triple-Negative Breast Carcinoma: NCT07441512 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Not yet recruiting
Recruitment status
26
Planned enrollment
2028-03-15
Primary-completion proxy
Executive view
NCT07441512 evaluates Eribulin mesylate in Advanced Triple-Negative Breast Carcinoma. The disclosed sponsor is Zhejiang Cancer Hospital, the design is Interventional, and the geographic footprint is Geography not reported. The first listed primary endpoint is ORR by Investigator assessment per RECIST 1.1, assessed over 22 months.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07441512 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Advanced Triple-Negative Breast Carcinoma landscape. Drug & Asset MCP drug_fetch was queried for Eribulin mesylate, while Company & Deal Intelligence MCP organization_fetch was queried for Zhejiang Cancer Hospital.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07441512 | Eribulin mesylate | Phase 2 / Not yet recruiting | Zhejiang Cancer Hospital | Geography not reported | ORR by Investigator assessment per RECIST 1.1 22 months | 2028-03-15 |
| CTRI/2026/06/113041 | Tislelizumab | Phase 4 / Not Yet Recruiting | Sponsor not reported | India | Timing not reported | |
| NCT07652242 | Olaparib | Phase 1 / Recruiting | Immunomic Therapeutics, Inc. | United States | Incidence of Dose-Limiting Toxicities as Assessed by CTCAE v5.0 21-28 days after the first vaccination | 2028-02-01 |
| NCT07646106 | The-0504 | Phase 1 / Recruiting | Thena Biotech S.R.L. | Italy | Assessment of Maximum Tolerated Dose (MTD) From enrollment to completion of Cycle 1 (each cycle is 21 days) | 2027-05-01 |
| NCT07630961 | [68Ga]Ga-NNS309 | Phase 1 / Recruiting | Novartis Pharmaceuticals Australia Pty Ltd. | Japan, Denmark | Part 1: Standard Uptake Value (SUV) of 68Ga-DFC413 uptake in organs and tumors over time Up to 240 minutes after 68Ga-DFC413 administration | 2028-01-16 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07441512 is a Phase 2, not yet recruiting study with 26 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “ORR by Investigator assessment per RECIST 1.1” over “22 months.” The retrieved endpoint description is: ORR by Investigator assessment per RECIST 1.1.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 26 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Advanced Triple-Negative Breast Carcinoma. These records do not establish direct evidence for NCT07441512 unless the registration number matches.
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given…
Phase 1/2; n=19; Number of Participants With DLTs in Each Module = 0 Participants ; Number of Participants With DLTs in Each Module = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05714553
A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer Wit…
Phase 1; n=12; Rate of Dose Limiting Toxicity (DLT) = 1 Participants ; Rate of Dose Limiting Toxicity (DLT) = 2 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04315233
Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metas…
Phase 1/2; n=5; Incidence of Dose Limiting Toxicities = 0 Participants ; Incidence of Dose Limiting Toxicities = 1 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05756166
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
No exact Drug & Asset MCP profile was returned for the protocol wording “Eribulin mesylate.” The report therefore avoids inferring modality, target or global development stage from the name alone.
Zhejiang Cancer Hospital is indexed in China with the website https://www.zchospital.com. Zhejiang Cancer Hospital is a cancer hospital that provides medical and rehabilitation services. The record lists 8 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Eribulin mesylate is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07441512
Protocol source: https://clinicaltrials.gov/study/NCT07441512
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
Eribulin mesylate in Advanced Triple-Negative Breast Carcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes ORR by Investigator assessment per RECIST 1.1 and 2028-03-15 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
